64 Y Combinator companies in Therapeutics, with team size, growth, open roles and funding.
Updated weekly, last on November 9, 2026. Roster from Y Combinator's public directory.
| Company | Batch | Team | 6 mo | 12 mo | Open roles | Total raised | Last round |
|---|---|---|---|---|---|---|---|
RNA medicines for liver diseases | W20 | 59 | −2% | −8% | 0 | $39.8M | Series A$30M, Oct 2022 |
Multimodal AI Platform for Modality Agnostic Drug Discovery™ | W19 | 50 | −2% | −6% | 0 | $26.6M | Undisclosed round$550K, Oct 2024 |
Unlocking the next generation of mRNA medicines | S21 | 35 | +21% | +35% | 0 | $70.9M | Series A$20M, Oct 2026 |
A self-help app for people to manage their ADHD. | S21Acquired | 30 | −6% | −21% | 0 | $14M | Series A$11M, Jan 2023 |
Discovering bispecific antibody drug-conjugates (BsADC) against cancer | W21 | 30 | −3% | +7% | 0 | $11.9M | Seed$11.8M, Oct 2025 |
Kernal is creating mRNA 2.0 therapies that work in specific cells | S20 | 21 | +5% | +40% | 3 | $73M | Grant$48M, Oct 2025 |
AI platform accelerating therapies for rare & inflammatory diseases. | S19 | 20 | +5% | +18% | 0 | $22.5M | Undisclosed round$5.5M, Dec 2025 |
mRNA therapeutics to extend healthspan entering clinical trials | S18 | 20 | 0% | 0% | 0 | $23.2M | Undisclosed round$2.1M, Sep 2026 |
Genetically engineered viruses that teach your immune system to kill… | S24 | 18 | +6% | +38% | 0 | $9.7M | Seed$9.1M, Jun 2026 |
We build better immunotherapies | S19 | 15 | −6% | 0 | $218M | Series C$55M, Apr 2024 | |
We bank your stem cells to help you live healthier, longer. | S17 | 15 | −6% | 0 | $2.6M | Undisclosed round$500K, Oct 2025 | |
Programmable DNA drug destroying all cancers, unlocking 80% of targets | X26 | 14 | 0 | $500K | YC investment$500K, Jun 2026 | ||
A nonprofit stool bank enabling access to fecal transplants. | W20 | 13 | −7% | +8% | 0 | $100K | Grant$100K, Jan 2022 |
We teach your immune system to attack and cure cancer | W23 | 11 | +10% | +22% | 0 | $500K | YC investment$500K, Apr 2023 |
Living therapies for pets first, and their people next | W19 | 10 | 0% | 0% | 0 | $475K | Grant$100K, May 2022 |
A platform to make artificial viruses as cancer therapeutics. | S21 | 9 | 0% | +13% | 0 | $4.1M | Seed$4M, Feb 2025 |
Regulating the immune system to block cancer & autoimmune diseases | S21 | 9 | 0% | 0% | 0 | $8.7M | Convertible note$4.5M, Nov 2023 |
Utilizing monogenic disorders to inform and solve highly complex… | S18 | 9 | +13% | 0 | $7.9M | Grant$3.7M, Nov 2021 | |
RNA intelligence for precision medicine | S25 | 8 | 0 | $7.3M | Seed$7.2M, May 2026 | ||
Building programmable therapeutics for the immune system | W24 | 8 | +33% | +33% | 0 | $7.6M | Seed$7.1M, Jul 2024 |
Cell-specific genetic medicines | W21 | 8 | 0% | −33% | 0 | $125K | YC investment$125K, Jan 2023 |
Human whole body end-of-life preservation for later revival. | W18 | 8 | 0 | $120K | Undisclosed round$120K, Jan 2021 | ||
Elevated mRNA for transformative medicines. | W24 | 7 | 0% | +17% | 0 | $13.5M | Seed$13M, May 2026 |
Oral drugs to halt neurodegeneration | W22 | 7 | +40% | +40% | 0 | Undisclosed roundMar 2022 | |
Altay develops disease-modifying therapies targeting transcription… | W20 | 7 | +17% | +40% | 0 | $40.2M | Series A$37M, Oct 2026 |
Smart gels for local drug delivery to the gut | W19 | 7 | +17% | +17% | 0 | $645K | Series A$250K, Nov 2021 |
YourChoice therapeutics is revolutionizing the contraceptive market… | W19 | 7 | 0% | +17% | 0 | $17.2M | Undisclosed round$500K, Jan 2025 |
Our drugs engage the immune system to fight tumors | W24 | 6 | −14% | −14% | 0 | $500K | YC investment$500K, Feb 2024 |
Combinations therapy by rational design | S22 | 6 | 0 | $650K | Undisclosed round$150K, Nov 2023 | ||
Targeting the Tumor Ecosystem to address cancer drug resistance. | W22 | 6 | 0% | 0% | 0 | $2.3M | Seed$1.8M, Oct 2024 |
Cloud AI microscopy automation | W21 | 6 | +20% | −33% | YC | $2.1M | Seed$2.1M, Jan 2022 |
Curative genetic medicines for kidney diseases | S20 | 6 | 0% | 0% | 0 | $20K | Seed$20K, Oct 2026 |
We are developing a drug to burn calories and increase metabolism… | W20 | 6 | 0% | 0% | 0 | $650K | Undisclosed round$500K, Jan 2022 |
Sigma Genetics is a biotechnology company that is building… | W17 | 6 | 0 | Non-equity supportMar 2026 | |||
Making Next-Generation Antibiotics that Outpace Bacterial Evolution | S24 | 5 | 0% | 0% | 0 | $500K | YC investment$500K, Sep 2024 |
Breakthrough medicines unlocking the biology of heme | W24 | 5 | 0% | 0% | 0 | $500K | YC investment$500K, Feb 2024 |
Platform injectable gel based therapeutic for osteoarthritis | S22 | 5 | 0 | $5.4M | Grant$4.9M, Nov 2024 | ||
Precision-first therapies | W19Inactive | 5 | 0% | 0% | 0 | $64M | Series A$52M, Jun 2022 |
Extrapolative AI to unlock First-in-Class drugs | S26 | 4 | 0 | ||||
Potent, durable, and redosable non-viral genetic medicines | W22Acquired | 4 | −64% | −60% | 0 | $3.9M | Seed$3.9M, May 2022 |
A therapeutics platform for curing inflammatory disorders | S21 | 4 | −20% | 0 | $125K | Seed$125K, Feb 2025 | |
The cure for hair loss. | S18Inactive | 4 | 0 | $2.7M | Seed$2.7M, Jan 2022 | ||
Tradewind translates scientific insight into innovative ways of… | W18 | 4 | −20% | −20% | 0 | $120K | YC investment$120K, Jan 2018 |
Engineering next-generation, brain-penetrant cancer therapies. | W18Inactive | 4 | 0 | $25M | Series A$25M, Feb 2021 | ||
Engineering the future of Cancer Drug Discovery | F26 | 3 | 0 | ||||
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs | W25 | 3 | 0 | $500K | YC investment$500K, Mar 2025 | ||
Redefining the Standard of Care for Iron Deficiency Anemia | S22 | 3 | 0 | Pre-seedAug 2022 | |||
Enabling Tissue Targeting of Therapies | S22 | 3 | 0 | $500K | YC investment$500K, Sep 2022 | ||
| W19 | 3 | 0 | $15M | Seed$4M, Aug 2023 | |||
Replacing organ transplant with an infusion | S18 | 3 | 0 | $4.4M | Grant$770K, May 2025 |
Every launched company in YC's public directory, with its batch, status, industry and location. New companies show up the week YC lists them.
Each company is matched to Crustdata by its website. Crustdata adds team size and its change over 6 and 12 months, open roles from job postings, reported funding, and founders' past employers.
Hiring the most counts distinct roles posted in the last 60 days. Growth needs 10+ people today, shrinking 20+ a year ago, so tiny teams do not top the lists. Rebuilt every week.
The numbers on this page come from three Crustdata API calls. Crustdata tags 5,000+ companies with Y Combinator as an investor; swap the filter for any investor, industry or headcount range and track your own list, with founders' work emails one call away.
# 1. every company with Y Combinator as an investor curl https://api.crustdata.com/company/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "field": "funding.investors", "type": "in", "value": ["Y Combinator"] }, "fields": ["basic_info.name", "headcount.total", "headcount.growth_percent", "funding.total_investment_usd"], "limit": 100 }' # 2. open listings per company, last 60 days (limit 0 = counts only) curl https://api.crustdata.com/job/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "op": "and", "conditions": [ { "field": "company.basic_info.company_id", "type": "in", "value": [...] }, { "field": "metadata.date_added", "type": "=>", "value": "2026-08-24" } ]}, "limit": 0, "aggregations": [{ "type": "group_by", "field": "company.basic_info.company_id", "agg": "count" }] }' # 3. the same company filter as a weekly watch: POST /watch/company/search
64 Y Combinator companies are in Therapeutics; 53 are active.
1 companies posted roles in the last 60 days, led by Kernal Biologics (3 roles). 1 mark themselves as hiring on YC's directory.
By team growth over 6 months (10+ people): Sensible Biotechnologies (+21%), Modulari-T (+10%) and Kopra Bio (+6%).
Largest latest rounds in the last 12 months, after their YC batch: Altay Therapeutics ($37M), Sensible Biotechnologies ($20M) and ParcelBio ($13M).